Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.
2.

NMR-based metabolomics: translational application and treatment of cancer.

Serkova NJ, Spratlin JL, Eckhardt SG.

Curr Opin Mol Ther. 2007 Dec;9(6):572-85. Review.

PMID:
18041668
3.

Advances in metabolic profiling.

Barrett D.

Bioanalysis. 2012 Mar;4(6):643-4. doi: 10.4155/bio.12.23.

PMID:
22452253
4.

Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.

Klawitter J, Kominsky DJ, Brown JL, Klawitter J, Christians U, Leibfritz D, Melo JV, Eckhardt SG, Serkova NJ.

Br J Pharmacol. 2009 Sep;158(2):588-600. doi: 10.1111/j.1476-5381.2009.00345.x. Epub 2009 Aug 6.

5.

Metabolomics of cancer.

Serkova NJ, Glunde K.

Methods Mol Biol. 2009;520:273-95. doi: 10.1007/978-1-60327-811-9_20.

PMID:
19381962
6.

Pattern recognition and biomarker validation using quantitative 1H-NMR-based metabolomics.

Serkova NJ, Niemann CU.

Expert Rev Mol Diagn. 2006 Sep;6(5):717-31. Review.

PMID:
17009906
7.

Hypoxia-induced metabolic shifts in cancer cells: moving beyond the Warburg effect.

Weljie AM, Jirik FR.

Int J Biochem Cell Biol. 2011 Jul;43(7):981-9. doi: 10.1016/j.biocel.2010.08.009. Epub 2010 Aug 24. Review.

PMID:
20797448
8.

Study on plasmatic metabolomics of Uygur patients with essential hypertension based on nuclear magnetic resonance technique.

Zhong L, Zhang JP, Nuermaimaiti AG, Yunusi KX.

Eur Rev Med Pharmacol Sci. 2014;18(23):3673-80.

9.

Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.

Morelli MP, Tentler JJ, Kulikowski GN, Tan AC, Bradshaw-Pierce EL, Pitts TM, Brown AM, Nallapareddy S, Arcaroli JJ, Serkova NJ, Hidalgo M, Ciardiello F, Eckhardt SG.

Clin Cancer Res. 2012 Feb 15;18(4):1051-62. doi: 10.1158/1078-0432.CCR-11-1507. Epub 2011 Dec 15.

10.

Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells.

Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, Armistead S, Lemire K, Orrell J, Teich J, Chomicz S, Ferrick DA.

Am J Physiol Cell Physiol. 2007 Jan;292(1):C125-36. Epub 2006 Sep 13.

11.

Principal component directed partial least squares analysis for combining nuclear magnetic resonance and mass spectrometry data in metabolomics: application to the detection of breast cancer.

Gu H, Pan Z, Xi B, Asiago V, Musselman B, Raftery D.

Anal Chim Acta. 2011 Feb 7;686(1-2):57-63. doi: 10.1016/j.aca.2010.11.040. Epub 2010 Nov 26.

12.

Quantitative analysis in magnetic resonance spectroscopy: from metabolic profiling to in vivo biomarkers.

Serkova NJ, Brown MS.

Bioanalysis. 2012 Feb;4(3):321-41. doi: 10.4155/bio.11.320. Review.

PMID:
22303835
13.

Metabolomics: a revolution for novel cancer marker identification.

Bu Q, Huang Y, Yan G, Cen X, Zhao YL.

Comb Chem High Throughput Screen. 2012 Mar;15(3):266-75. Review.

PMID:
22221059
14.

Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential.

Pelicano H, Zhang W, Liu J, Hammoudi N, Dai J, Xu RH, Pusztai L, Huang P.

Breast Cancer Res. 2014 Sep 11;16(5):434. doi: 10.1186/s13058-014-0434-6.

15.

Stable isotope-resolved metabolomics and applications for drug development.

Fan TW, Lorkiewicz PK, Sellers K, Moseley HN, Higashi RM, Lane AN.

Pharmacol Ther. 2012 Mar;133(3):366-91. doi: 10.1016/j.pharmthera.2011.12.007. Epub 2011 Dec 23. Review.

16.

Clinical applications of metabolomics in oncology: a review.

Spratlin JL, Serkova NJ, Eckhardt SG.

Clin Cancer Res. 2009 Jan 15;15(2):431-40. doi: 10.1158/1078-0432.CCR-08-1059. Review.

17.
18.

Glucose avidity of carcinomas.

Ortega AD, Sánchez-Aragó M, Giner-Sánchez D, Sánchez-Cenizo L, Willers I, Cuezva JM.

Cancer Lett. 2009 Apr 18;276(2):125-35. doi: 10.1016/j.canlet.2008.08.007. Epub 2008 Sep 14. Review.

PMID:
18790562
19.

Dynamic phosphometabolomic profiling of human tissues and transgenic models by 18O-assisted ³¹P NMR and mass spectrometry.

Nemutlu E, Zhang S, Gupta A, Juranic NO, Macura SI, Terzic A, Jahangir A, Dzeja P.

Physiol Genomics. 2012 Apr 2;44(7):386-402. doi: 10.1152/physiolgenomics.00152.2011. Epub 2012 Jan 10.

20.

The promise of metabolomics in cancer molecular therapeutics.

Fan TW, Lane AN, Higashi RM.

Curr Opin Mol Ther. 2004 Dec;6(6):584-92. Review.

PMID:
15663322

Supplemental Content

Support Center